Tag: Bausch lomb

Ophthalmic drug products pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body's natural defenses. Given this, consumers frequently ask, is there a recall on Muro 128 Ointment?

In September 2023, Bausch + Lomb announced the completion of its acquisition of Xiidra from Novartis, a transaction that has prompted many patients to question if the drug is being phased out. The good news is that for patients wondering, 'Is Xiidra being discontinued in the USA?', the answer is no; the medication remains fully available for prescription.

In clinical trials, Lumify demonstrated significant redness reduction in as little as one minute. But **what's so special about Lumify eye drops** beyond their speed? The key lies in their unique active ingredient and selective mechanism of action, which offer a safer alternative to older, decongestant-based products.

In 2023, eye health company Bausch + Lomb acquired Xiidra from Novartis in a deal worth up to $2.5 billion. For patients wondering, “Is Xiidra being discontinued?”, this change in ownership confirms the medication's continued availability and future in the dry eye treatment market.

The average retail price for a single 5g tube of Zirgan eye gel is over $570, a significant cost for many patients [1.2.2]. This article explores effective strategies for how to get Zirgan cheaper, from manufacturer programs to prescription discount cards.

Corneal edema, a condition involving swelling of the eye's cornea, can occur in 6.2% to 11.3% of patients after eye surgery [1.8.1, 1.8.2]. For this, many turn to hypertonic saline treatments. So, what are the side effects of Muro 128 eye ointment, a common therapy?

With an average cash price often exceeding $800 for a 30-day supply, many patients naturally wonder, "Why are Xiidra eye drops so expensive?". The high cost is largely a product of its status as a brand-name pharmaceutical with patent protection, high research and development costs, and a unique mechanism of action.

As of October 2025, a recall for the prescription medication Xiidra has not been issued. However, confusion may stem from a specific recall of *over-the-counter* (OTC) eye drops and past manufacturing issues, leading many to ask, 'Has Xiidra been recalled?'.

Yes, on December 22, 2017, the U.S. Food and Drug Administration (FDA) first approved LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) as an over-the-counter (OTC) medication for the treatment of ocular redness. This approval was notable as it introduced a new active ingredient to the OTC market for this purpose, offering a different approach to eye redness relief.

A medication guide for Muro 128 5% eye drops specifies that once opened, the product must be used within 30 days and any unused portion should be discarded. This rule is critical for preventing eye infections and ensuring the medication's effectiveness. But why is this 'beyond-use date' so important?